Mark Schoenberg - 31 Oct 2021 Form 4 Insider Report for UroGen Pharma Ltd. (URGN)

Role: Chief Medical Officer
Signature: /s/ Jason Smith, Attorney-in-Fact
Issuer symbol: URGN
Transactions as of: 31 Oct 2021
Net transactions value: -$4,427
Form type: 4
Filing time: 02 Nov 2021, 15:45:03 UTC
Previous filing: 28 Oct 2021
Next filing: 19 Nov 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	URGN	Ordinary Shares	Options Exercise		+500	+2.3%		22,095	31 Oct 2021	Direct	F1
transaction	URGN	Ordinary Shares	Sale	$4,427	-258	-1.2%	$17.16	21,837	01 Nov 2021	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	URGN	Restricted Stock Units	Options Exercise	$0	-500	-17%	$0.000000	2,500	31 Oct 2021	Ordinary Shares	500		Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer
F2	Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units
F3	The reporting person was granted restricted stock units ("RSUs") on January 31, 2020 representing 6,000 ordinary shares. 33.33% of the RSUs vested on January 31, 2021 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter.